Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 1
2021 3
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

4 results

Results by year

Filters applied: . Clear all
Page 1
Risk of Cataract in Intermediate Uveitis.
Minkus CL, Pistilli M, Dreger KA, Fitzgerald TD, Payal AR, Begum H, Kaçmaz RO, Jabs DA, Nussenblatt RB, Rosenbaum JT, Levy-Clarke GA, Sen HN, Suhler EB, Thorne JE, Bhatt NP, Foster CS, Buchanich JM, Kempen JH; Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study Research Group. Minkus CL, et al. Am J Ophthalmol. 2021 Sep;229:200-209. doi: 10.1016/j.ajo.2021.02.032. Epub 2021 Mar 10. Am J Ophthalmol. 2021. PMID: 33713679 Free PMC article.
DESIGN: Retrospective cohort study. METHODS: Patients were identified from the Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study, in which medical records were reviewed to determine demographic and clinical data of every eye/patient at every visit at 5 parti …
DESIGN: Retrospective cohort study. METHODS: Patients were identified from the Systemic Immunosuppressive Therapy for Eye Diseases Co …
Corneal Endothelial Transplantation in Uveitis: Incidence and Risk Factors.
Roldan AM, Zebardast N, Pistilli M, Khachatryan N, Payal A, Begum H, Artornsombudh P, Pujari SS, Rosenbaum JT, Sen HN, Suhler EB, Thorne JE, Bhatt NP, Foster CS, Jabs DA, Levy-Clarke GA, Nussenblatt RB, Buchanich JM, Kempen JH; Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study Research Group. Roldan AM, et al. Am J Ophthalmol. 2022 Apr;236:288-297. doi: 10.1016/j.ajo.2021.10.031. Epub 2021 Nov 13. Am J Ophthalmol. 2022. PMID: 34780793 Free PMC article.
METHODS: Adult patients attending United States tertiary uveitis care facilities diagnosed with noninfectious ocular inflammation were identified from the Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study. Time-to-event analysis was used to estimate the inci …
METHODS: Adult patients attending United States tertiary uveitis care facilities diagnosed with noninfectious ocular inflammation were ident …
Incidence of and Risk Factors for Cataract in Anterior Uveitis.
Papaliodis GN, Rosner BA, Dreger KA, Fitzgerald TD, Artornsombudh P, Kothari S, Gangaputra SS, Levy-Clarke GA, Nussenblatt RB, Rosenbaum JT, Sen HN, Suhler EB, Thorne JE, Bhatt NP, Foster CS, Jabs DA, Pak CM, Ying GS, Kempen JH; Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study Research Group. Papaliodis GN, et al. Am J Ophthalmol. 2023 Oct;254:221-232. doi: 10.1016/j.ajo.2023.06.021. Epub 2023 Jul 5. Am J Ophthalmol. 2023. PMID: 37414328
Remission of Non-Infectious Anterior Scleritis: Incidence and Predictive Factors.
Kempen JH, Pistilli M, Begum H, Fitzgerald TD, Liesegang TL, Payal A, Zebardast N, Bhatt NP, Foster CS, Jabs DA, Levy-Clarke GA, Nussenblatt RB, Rosenbaum JT, Sen HN, Suhler EB, Thorne JE; Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study Research Group. Kempen JH, et al. Am J Ophthalmol. 2021 Mar;223:377-395. doi: 10.1016/j.ajo.2019.03.024. Epub 2019 Apr 3. Am J Ophthalmol. 2021. PMID: 30951689
Factors predictive of less scleritis remission included scleritis bilaterality (adjusted hazard ratio [aHR] = 0.46, 95% CI: 0.32-0.65); and diagnosis with any systemic inflammatory disease (aHR = 0.36, 95% CI: 0.23-0.58), or specifically with Rheumatoid Arthritis (aHR = 0. …
Factors predictive of less scleritis remission included scleritis bilaterality (adjusted hazard ratio [aHR] = 0.46, 95% CI: 0.32-0.65); and …